709-P: Persons with High-Risk Diabetes, Depression, and Stress Using a Digital Health Platform Experience an Improvement in Glycemic Management

Abstract

Introduction: As the prevalence of type 2 diabetes (T2D) continues to grow worldwide, individuals struggle with how to integrate diabetes self-management into their lives. This is complicated by the high rate of depression and stress among persons with T2D. A multicondition behavior change-oriented digital therapeutic platform may alleviate the burdens faced by persons with comorbid diabetes and mental health conditions. Objective: To investigate blood glucose levels outcomes in persons with T2D and comorbid depression and stress who used a multicondition digital therapeutic to manage their blood glucose levels. Method: We performed a retrospective data analysis on the DarioTM database using users who activated the mobile app during 2019-2021 and who self-reported stress and depression in the App questionnaire. Participants who took at least 5 measurements at 1st and 12th month with Dario and who started with an average blood glucose >180 mg/dL were termed “high-risk.” The ratios assessed were average blood glucose and high blood glucose (>180 mg/dL) readings ratio over a year. Results: The high-risk group of 491 users significantly reduced their average blood glucose by 13% (204±60 vs. 234±55) (P<0.001) . A subset of high-risk users with type 2 (N=379) was also evaluated and significantly reduced their average blood glucose by 14% (P<0.001) (201±66 vs. 233±53) . Moreover, their high glucose events ratio (>180 mg/dL) was significantly reduced from 69.4% to 46.9% over a full year usage (P<0.001) . Conclusion: The use of a multicondition digital therapeutic platform may be associated with improved glucose management for persons with “high risk” glycemia who cope with depression and stress. The present study revealed that the digital multicondition platform has the potential to enhance self-care behaviors among people with diabetes that suffer from stress and depression. Disclosure Y.Hershcovitz: None. M.Tamir: None. M.D.Ritholz: Advisory Panel; DarioHealth Corp. O.Manejwala: Employee; DarioHealth Corp., Stock/Shareholder; DarioHealth Corp.